Oculis Holding AG
NASDAQ:OCS
Oculis Holding AG
Other
Oculis Holding AG
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Other
-CHf87k
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Other
-$294m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-54%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Other
-$386.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Other
-CHf1.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
0%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Other
-$4m
|
CAGR 3-Years
83%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
What is Oculis Holding AG's Other?
Other
-87k
CHF
Based on the financial report for Dec 31, 2025, Oculis Holding AG's Other amounts to -87k CHF.
What is Oculis Holding AG's Other growth rate?
Other CAGR 3Y
25%
Over the last year, the Other growth was 97%. The average annual Other growth rates for Oculis Holding AG have been 25% over the past three years .
